Anika Therapeutics, Inc. (ANIK) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ANIK Revenue Growth
Revenue Breakdown (FY 2023)
ANIK's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
By Geography
ANIK Revenue Analysis (2014–2025)
As of May 6, 2026, Anika Therapeutics, Inc. (ANIK) generated trailing twelve-month (TTM) revenue of $116.3 million, reflecting strong growth of +13.2% year-over-year. The most recent quarter (Q1 2026) recorded $29.6 million in revenue, down 3.3% sequentially.
Looking at the longer-term picture, ANIK's 5-year compound annual growth rate (CAGR) stands at -2.9%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $147.8 million in 2021.
Revenue diversification analysis shows ANIK's business is primarily driven by Joint Preservation and Restoration (85%), and Non-Orthopedic (15%). With over half of revenue concentrated in Joint Preservation and Restoration, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MDXG (+10.5% YoY), NVCR (+8.5% YoY), and OSUR (-47.3% YoY), ANIK has underperformed the peer group in terms of revenue growth. Compare ANIK vs MDXG →
ANIK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ANIKCurrent | $116M | +13.2% | -2.9% | -9.8% | |
 MDXG | $419M | +10.5% | +11.0% | 15.3% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 OSUR | $115M | -47.3% | -7.7% | -59.2% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 LNTH | $1.5B | +0.5% | +35.3% | 20.2% |
ANIK Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $112.8M | -5.9% | $63.8M | 56.6% | $-11,051,000 | -9.8% |
| 2024 | $119.9M | -0.7% | $76.0M | 63.4% | $-5,101,000 | -4.3% |
| 2023 | $120.8M | +6.1% | $82.5M | 68.3% | $844K | 0.7% |
| 2022 | $113.8M | -23.0% | $73.2M | 64.3% | $3.7M | 3.2% |
| 2021 | $147.8M | +13.3% | $82.9M | 56.1% | $2.6M | 1.8% |
| 2020 | $130.5M | +13.8% | $69.0M | 52.9% | $-28,322,000 | -21.7% |
| 2019 | $114.6M | +8.6% | $85.9M | 74.9% | $34.2M | 29.9% |
| 2018 | $105.6M | -6.9% | $74.3M | 70.4% | $21.7M | 20.6% |
| 2017 | $113.4M | +9.7% | $86.1M | 75.9% | $45.7M | 40.3% |
| 2016 | $103.4M | +11.2% | $79.4M | 76.8% | $50.6M | 49.0% |
See ANIK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANIK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANIK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonANIK — Frequently Asked Questions
Quick answers to the most common questions about buying ANIK stock.
Is ANIK's revenue growth accelerating or slowing?
ANIK maintains +13.2% revenue growth, in line with its 5-year CAGR of -2.9%. TTM revenue stands at $116M. Growth rate remains consistent with historical average.
What is ANIK's long-term revenue growth rate?
Anika Therapeutics, Inc.'s 5-year revenue CAGR of -2.9% reflects the sustained expansion pattern. Current YoY growth of +13.2% is near this long-term average.
How is ANIK's revenue distributed by segment?
ANIK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.